Sector News

Lilly announces new $4.5 Billion site

October 6, 2024
Life sciences

Eli Lilly and Company (Lilly) recently announced a $4.5 billion (€4.07 billion) investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.

The facility will enable Lilly to research new methods of producing medicines and scale up manufacturing for clinical trials. The first-ever facility of its kind, combining research and manufacturing in a single location, the Medicine Foundry will be located in Indiana’s LEAP Research and Innovation District in Lebanon, Indiana, expanding the company’s investment in the area to over $13 billion (€11.75 billion).

“As we accelerate our work to discover new medicines for the toughest diseases, we’re continuing to invest in state-of-the-art infrastructure to support our growing pipeline,” said David A. Ricks, Lilly’s chair and CEO. “In addition to supplying high-quality medicine for our clinical studies, this new complex will further strengthen our process development and scale up our manufacturing capabilities to speed delivery of next-generation medicines to patients around the world.”

The Medicine Foundry will enable Lilly to develop innovative manufacturing solutions, increase capacity for clinical trial medicines, and reduce costs and environmental impact. This flexible facility will produce various molecular therapies and transfer new technologies to other Lilly sites. Located in Indiana’s LEAP Research and Innovation District, it will support collaboration with Lilly Research Laboratories in Indianapolis and manufacturing sites in Lebanon. Indiana will provide infrastructure improvements and economic incentives, and the facility is expected to create 400 full-time jobs.

This new facility will add to Lilly’s previous manufacturing commitments in Lebanon:

  • In May 2022, Lilly announced plans to invest $2.1 billion (€1.9 billion) in two new manufacturing sites in Lebanon to expand its network for active ingredients and new modalities, such as genetic medicines.
  • In April 2023, Lilly broke ground on these facilities and announced an additional $1.6 billion (€1.45 billion) investment.
  • In May 2024, Lilly announced an additional $5.3 billion (€4.79 billion) commitment to enhance capacity to manufacture active pharmaceutical ingredients for its latest diabetes and obesity medicines. This milestone marked the largest single investment in active pharmaceutical ingredients production in U.S. history.

Source: chemanager-online.com

comments closed

Related News

November 9, 2024

Biologics CDMO Avid Bioservices to go private with $1.1B sale to Ampersand, GHO Capital

Life sciences

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital Partners is pulling out its life sciences checkbook once again. This week, biologics CDMO Avid Bioservices revealed that it’s agreed to be acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth $1.1 billion.

November 9, 2024

Ardena expands European bioanalytical capabilities

Life sciences

Belgium-headquartered CDMO Ardena announced plans to expand its bioanalytical services in the Netherlands. As part of the investment, the company plans to establish a new bioanalytical laboratory at its Pivot Park facility in Oss, as well as additional capacity and new GLP capabilities at its bioanalytical center of excellence in Assen.

November 9, 2024

Argenx’ Vyvgart launch in CIDP picks up as the company barrels toward 10 indications by 2030

Life sciences

Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’s Vyvgart is already making headway in the rare disease space, just one of the long-term growth indications for the versatile medicine.

How can we help you?

We're easy to reach